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Abstract
Background: Triple-negative breast cancer (TNBC), lacking expression of hormone and human epidermal growth 
factor receptor 2 receptors, is an aggressive subtype that frequently metastasizes to the brain and has no FDA-
approved systemic therapies. Previous literature demonstrates mitogen-activated protein kinase kinase (MEK) 
pathway activation in TNBC brain metastases. Thus, we aimed to discover rational combinatorial therapies with 
MEK inhibition, hypothesizing that co-inhibition using clinically available brain-penetrant inhibitors would improve 
survival in preclinical models of TNBC brain metastases.
Methods: Using human-derived TNBC cell lines, synthetic lethal small interfering RNA kinase screens were eval-
uated with brain-penetrant inhibitors against MEK1/2 (selumetinib, AZD6244) or phosphatidylinositol-3 kinase 
(PI3K; buparlisib, BKM120). Mice bearing intracranial TNBC tumors (SUM149, MDA-MB-231Br, MDA-MB-468, or 
MDA-MB-436) were treated with MEK, PI3K, or platelet derived growth factor receptor (PDGFR; pazopanib) inhibi-
tors alone or in combination. Tumors were analyzed by western blot and multiplexed kinase inhibitor beads/mass 
spectrometry to assess treatment effects.
Results: Screens identified MEK+PI3K and MEK+PDGFR inhibitors as tractable, rational combinations. Dual 
treatment of selumetinib with buparlisib or pazopanib was synergistic in TNBC cells in vitro. Both combinations 
improved survival in intracranial SUM149 and MDA-MB-231Br, but not MDA-MB-468 or MDA-MB-436. Treatments 
decreased mitogen-activated protein kinase (MAPK) and PI3K (Akt) signaling in sensitive (SUM149 and 231Br) 
but not resistant models (MDA-MB-468). Exploratory analysis of kinome reprogramming in SUM149 intracranial 
tumors after MEK ± PI3K inhibition demonstrates extensive kinome changes with treatment, especially in MAPK 
pathway members.
Conclusions: Results demonstrate that rational combinations of the clinically available inhibitors selumetinib 
with buparlisib or pazopanib may prove to be promising therapeutic strategies for the treatment of some TNBC 
brain metastases. Additionally, effective combination treatments cause widespread alterations in kinase pathways, 
including targetable potential resistance drivers.
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triple-negative breast cancer
Triple-negative breast cancer (TNBC) is an aggressive sub-
type which lacks expression of the estrogen and progester-
one receptors and human epidermal growth factor receptor 
2 (HER2). TNBC is commonly classified as either the basal-
like or claudin-low molecular subtype by gene expres-
sion analysis, subtypes that have a predilection for brain 
relapse.1–3 Nearly 50% of TNBC patients with advanced 
disease will present with CNS recurrence.4,5 Survival 
after TNBC brain metastases (BM) diagnosis is less than 
6 months.4,5 A lack of targeted agents for TNBC BM coupled 
with the unique biology of TNBC, BM, and the blood–brain 
barrier (BBB) continue to thwart effective therapeutics.4,6,7
While breast cancer brain metastases (BCBM) have com-
promised the BBB, they exhibit a wide heterogeneity of 
permeability and are overall less permeable than extracra-
nial metastases.8,9 Non-brain-penetrant drugs do not reach 
effective doses in BM,8,9 while liposomal-packaged drugs 
with increased brain penetration demonstrate increased 
efficacy.10,11 Thus, brain-penetrant, targeted systemic thera-
pies are needed to effectively treat patients with TNBC BM.
The mitogen-activated protein kinase kinase/extracellu-
lar signal-regulated kinase (MEK/ERK) pathway is activated 
in both TNBC and BM,12,13 thus providing a possible target 
for therapeutic intervention. Activation of this pathway 
in BM enhances colonization, survival, and growth.13,14 
TNBC specifically is initially sensitive to MEK inhibition in 
vivo,15,16 but resistance ensues without combinatorial ther-
apy due to kinome reprogramming.17 Dual inhibition strat-
egies involving MEK are needed for increased efficacy.16–19
Two potential compensatory pathways include the 
phosphatidylinositol-3 kinase (PI3K) and platelet-derived 
growth factor receptors (PDGFRα/β) pathways. Basal-
like tumors exhibit the highest activation of the PI3K and 
PDGFR pathways among the breast cancer subtypes,12,20–22 
and BM exhibit even greater activation of the PI3K path-
way than primary breast tumors.13,23,24 PDGFR plays an 
important role in the epithelial-to-mesenchymal transition–
mediated process of TNBC shifting from nonstem to cancer 
stem cells20 and in the neuro-inflammatory response by 
astrocytes to BCBM.25
Combination therapy must be achieved with brain-pen-
etrant molecules to effectively treat patients with TNBC 
BM. We hypothesized that synthetic-lethal hits from a 
kinome small interfering (si)RNA screen with MEK inhibi-
tors would be effective as combinatorial therapy in intrac-
ranial TNBC models. We investigated 3 clinically available 
brain-penetrant inhibitors against MEK1/2 (selumetinib, 
AZD6244),26,27 pan-PI3K (buparlisib, BKM120),19 and 
PDGFRα/β (pazopanib, Votrient),28,29 which have also shown 
promise in prior preclinical studies of extracranial TNBC. 
Selumetinib, combined with inhibition of PI3K or PDGFRβ, 
induces tumor regression and increases survival in primary 
TNBC mouse models.17,18 Buparlisib alone reduces tumor 
growth in a genetically engineered mouse TNBC model and 
patient-derived xenografts.30 In a mouse BCBM model, paz-
opanib reduces the number and size of brain metastases.14 
Our results in 4 intracranial TNBC models provide preclini-
cal data for early-phase clinical trials in TNBC BM patients.
Materials and Methods
Cell Lines
The human-derived TNBC cell lines SUM149 (Asterand; 
basal-like BRCA1-mutant, PTEN−), MDA-MB-231Br (Dr 
Toshiyuki Yoneda; claudin-low BRCA1-wildtype, PTEN-
wildtype, KRAS-mutant, BRAF-mutant), MDA-MB-468 
(American Type Culture Collection [ATCC]; basal-like BRCA1-
wildtype, PTEN−), and MDA-MB-436 (ATCC; claudin-low 
BRCA1-mutant, PTEN−) (Fig. 1A) were transfected with 
luciferase vector under control of a cytomegalovirus pro-
moter as described,31,32 were confirmed mycoplasma free 
(September 2015), and were verified by gene expression 
(September 201031,32). Cell lines were cultured in Invitrogen 
media with antibiotic-antimycotic additive and maintained 
at 37°C with 5% CO2: SUM149 in HuMEC + supplements + 
5% fetal bovine serum (FBS), MDA-MB-468 in Roswell Park 
Memorial Institute 1640 medium + 10% FBS with plug seal 
capped flasks (Corning), MDA-MB-231Br and MDA-MB-436 
in high glucose Dulbecco’s modified Eagle’s medium + 10% 
FBS. See Supplementary material for additional details.
Drugs
Buparlisib, selumetinib, and pazopanib (Chemietek) 
(Supplementary Table S1) were diluted in dimethyl sulfox-
ide (DMSO) in vitro. Dosing, schedule, and administration 
routes (Supplementary Table S1) were conducted as pub-
lished for in vivo studies.14,18 As monotherapy, buparlisib 
(30 mg/kg/day) and selumetinib (37 mg/kg/day) were deliv-
ered in the chow, while pazopanib was given at 200 mg/kg 
by oral gavage daily. In combination, doses were reduced 
to 25 mg/kg/day buparlisib + 18 mg/kg/day selumetinib and 
125/mg/kg/day pazopanib + 18 mg/kg/day selumetinib.
Importance of the study
There are currently no FDA-approved systemic treat-
ments for TNBC brain metastases. This study supports 
the combined use of brain-penetrant inhibitors against 
the MEK pathway with either PI3K or PDGFR inhibition to 
more effectively treat patients with TNBC brain metasta-
ses. In sensitive TNBC models, combination treatments 
proved synergistic in vitro and effective in vivo, nearly 
doubling or tripling survival compared with controls, 
depending on the model. Although these combinations 
did not prove effective in all models tested, collective 
results demonstrate that a population of patients with 
TNBC brain metastases may benefit from these treat-
ment strategies. As the inhibitors tested are already 
clinically available for other indications, this strategy 
could be quickly translated to the design of TNBC brain 
metastases trials to address this medically unmet need.
In Vitro Chemosensitivity Drug and Synergy 
Studies
Cells were harvested and plated into 384-well, flat-bot-
tom plates (MicroFlo Select, Biotek Instruments) at a 
density of 600 (SUM149) or 550 (231Br) cells per well. 
For determinations of half-maximal inhibitory concen-
tration (IC50), buparlisib, selumetinib, or pazopanib was 
added to cells 24 hours after plating on duplicate plates 
(Biomek FXP automated system, Beckman Coulter). For 
synergy studies, DMSO, selumetinib, and/or buparlisib 
or pazopanib was added to cells 24 hours after plating 
Fig. 1 Potency, efficacy, and synergy of buparlisib, selumetinib, and pazopanib in four TNBC human-derived cancer cell lines in vitro. (A) Utilized 
cell lines, with their molecular classifications and relevant known mutational statuses. Drug response curves of SUM149 (149), MDA-MB-231Br 
(231Br), MDA-MB-468 (468), and MDA-MB-436 (436) TNBC cells after 72 hours with (B) buparlisib, (C) selumetinib, or (D) pazopanib. Synergy 
fraction affected (FA) versus combination index (CI) curves quantification for combined (E) buparlisib+selumetinib or (F) selumetinib+pazopanib 
in 149, 231Br, 468, and 436. CI categories: synergistic: <0.1–0.9, additive: 0.9–1.1, antagonistic: >1.1.
(Chou–Talalay method).33 Cell viability was assessed via 
CellTiterGlo (Promega) luminescence (Pherastar FS plate 
reader, BMG Labtech) at 72 hours after adding drug(s). See 
Supplementary material for additional details.
High-Throughput siRNA Screens for Synthetic 
Lethality
A human RNA interference (RNAi) library (Dharmacon)34 
containing 4 pooled siRNAs against 720 kinases was 
applied to SUM149 and MDA-MB-231Br. siRNAs on 384-
well plates were resuspended in media and transfec-
tion reagent (Dharmafect 2, Dharmacon, or RNAiMax, 
Invitrogen). After 30 minutes, 600 (SUM149) or 550 (231Br) 
cells per well were added. After 24 hours, media containing 
DMSO, buparlisib, or selumetinib were added to triplicate 
plates at the calculated IC25 concentration. Cell viability 
was assessed at 72 hours after drug addition. A validation 
screen with 58 siRNAs (Dharmacon) was then conducted.
In Vivo Efficacy and Pharmacodynamic Studies
In vivo studies were conducted as previously described31 
according to the Institutional Animal Care and Use 
Committee (IACUC) (12.059, 15.038). Briefly, 200 000 cells 
in 5 μL of 5% methylcellulose + culture media or phosphate 
buffered saline + 0.5% FBS were stereotactically injected 
into the right caudate nucleus of the basal ganglia using 
a 27-gauge needle. All 4 TNBC models achieved a >95% 
intracranial take rate. Drug doses and routes of adminis-
tration (above, Supplementary Table S1) were based on 
previously conducted maximum tolerated dose studies.18 
Treatment began the day after randomization (day 8 post-
injection for 231Br, day 15 for all other models to normalize 
for differential growth rates between models and main-
tain treatment initiation at 30%–40% of respective median 
survivals). For pharmacodynamic studies, mice were sac-
rificed at 2 weeks posttreatment or due to poor health.31 
Mice in the combination 5-2 groups were harvested follow-
ing a 2-day drug holiday. For survival studies, mice were 
sacrificed due to poor health or prespecified post-injection 
date (per IACUC protocol). Tumor burden was assessed 
weekly following tumor cell implantation by IVIS Lumina 
Camera (Caliper Life Sciences) imaging of the luciferase-
positive cells and quantified with Living Image 4.0 Software 
(Caliper Life Sciences) as photons/second after correction 
for background signal.31 Intracranial tumors were immedi-
ately dissected and stored at −80°C. For histology, whole 
brains were fixed in 10% formalin prior to processing for 
hematoxylin and eosin staining.31
Western Blot Analysis
Tumors were homogenized (Fisher PowerGen Model 125 
Homogenizer) for 3 × 10 seconds in lysis buffer consisting 
of 1/2X phosphate buffered saline + 2.0% NP-40 + 1 mM 
DL-dithiothreitol (Sigma 43819) + Roche cOmplete Protease
Inhibitor Cocktail (11697498001)  +  Phosphatase Inhibitor
Cocktail II (Sigma P-5726) + Phosphatase Inhibitor Cocktail
III (Sigma P-0044) per manufacturer’s instructions. Lysates
were centrifuged for 12 minutes at 14 000 relative cen-
trifugal force at 4°C, and supernatants were stored at 
−80°C. Bicinchoninic acid assay (Pierce 23225)  was used
to calculate protein concentrations. Proteins were sepa-
rated on NuPage Novex Midi 4–12% Bis-Tris sodium
dodecyl sulfate (SDS)–polyacrylamide gel electrophore-
sis gels (ThermoFisher Scientific) prior to transfer to 0.45
micron Hybond-P polyvinylidene difluoride membranes
(Amersham RPN303F). The following Cell Signaling (unless 
otherwise noted) antibodies were used per manufacturer’s
instructions: pAkt (Ser473, 9271), total Akt (9272), pERK1/2
(p44/42 MAPK Thr202/Tyr204, 4370), total ERK1/2 (p44/42
MAPK, 4695), pMEK1/2 (Ser217/221, 9154), total MEK1/2
(9122), β-actin (Sigma A5316).
Multiplex Inhibitor Beads/Mass Spectrometry
Intracranial SUM149 tumors treated for 2 weeks (pharma-
codynamic tumors) with control, buparlisib, selumetinib, 
or combination chow were lysed (n = 4/treatment) and pro-
cessed for global activated kinome profiling as described 
previously.35 Briefly, lysates were flowed over affinity col-
umns packed with kinase inhibitor resin, bound to kinase-
bound inhibitor beads, washed with high- and low-salt 
buffers followed by 0.1% SDS, and eluted in buffer contain-
ing 0.5% SDS by boiling. Samples were purified using meth-
anol chloroform extraction, trypsin digested, and cleaned 
via ethyl acetate extraction and Pepclean C-18 columns 
before being analyzed on a Thermo Q-Exactive ESI mass 
spectrometer. Spectra were searched using MaxQuant 
v1.5.1.2 software, and protein intensities were quantified 




Screen cell viability data were quantile normalized and log 
transformed. Genes were tested between control and treat-
ment with the significance analysis of microarray.36 Genes 
which decreased viability with treatment were prioritized 
with a false discovery rate ≤ 0.1. For the 231Br validation 
screen, a t-test for each gene was performed with P < 0.1 
considered further.
IC50 and synergy
IC50, 50% growth inhibition (GI50), maximum inhibition 
(Imax), and Hill slope values were calculated (GraphPad 
Prism v6) from 2–5 independent experiments for each cell 
line. Synergy determinations were conducted according to 
the Chou–Talalay method.33 See the Supplementary mate-
rial for additional details.
In vivo efficacy (survival and tumor burden)
Survival data were analyzed using the Kaplan–Meier 
method (GraphPad Prism). For the SUM149 and 231Br mod-
els, the results from 2 independent cohorts were pooled, as 
no significant differences were evident between cohorts. 
Additional details are in the Supplementary material.
Western blots
For 14-day treated tumors, ANOVA followed by paired 
t-tests with Tukey multiple correction was used to compare
the ratios of the band intensities of phosphorylated to total
protein levels for pERK/ERK, pAkt/Akt, and pMEK/MEK.
Multiplexed kinase inhibitor beads/mass spectrometry
Label-free quantification (LFQ) normalized values were fil-
tered to kinases and ranked. Missing values were imputed 
via multiple imputation, assuming that the abundances of 
unobserved values were less than the observed LFQ val-
ues within a sample. For each kinase, 20 imputed datasets 
were generated, collated, and analyzed by Kruskal–Wallis. 
Results were combined using Rubin’s Rules. Pairwise com-
parisons between control versus treatment group were run 
using t-tests followed by false discovery rate. Adjusted P 
(Q) < 0.1 was considered significant. Kinome tree diagrams
of treatment effects relative to controls were reproduced
courtesy of Cell Signaling Technology (www.cellsignal.
com). See Supplementary material for additional details.
Results
Synthetic Lethality Screens Identify Multiple 
Rational Co-targets with MEK Inhibition in TNBC
A synthetic enhancement of lethality screen was per-
formed in 2 human-derived TNBC cell lines capable of 
forming intracranial tumors in mice, SUM149 and MDA-
MB-231Br, using PI3K and MEK inhibitors (Fig.  1A). 
Exposure of SUM149 and MDA-MB-231Br (231Br) cells to 
the MEK1/2 inhibitor selumetinib or the pan-PI3K inhibi-
tor buparlisib yielded several co-target kinase pathways 
that enhanced lethality (Table 1, Supplementary Table S2). 
Knockdown of genes within the same pathway as the indi-
vidual drug treatment enhanced the effects of the drug. 
Increased lethality with selumetinib occurred when com-
bined with siRNA-mediated knockdown of other MAPK/
MEK pathway genes: BRAF, RAF1, MEK1, and MAP2K2/
MEK2. Similarly, knockdown of PI3K pathway genes 
(AKT1, PIK3CB, AKT2, and RPS6KB1) enhanced the effects 
of buparlisib.
Several promising genes emerged as synthetically 
lethal with MEK inhibitor treatment: PI3K subunit genes 
(PIK3C2B/C3/CB/CD), cell cycle regulators (CDK2/3/5/6, 
Table 1 Synthetically lethal genes in the siRNA screens in SUM149 and MDA-MB-231Br TNBC cells with PI3K or MEK inhibition*
Drug Selumetinib Buparlisib
Cell Line SUM149 MDA-MB-231Br Combined SUM149 MDA-MB-231Br Combined
Dose (IC25) 200 nM 5.04 µM N/A 810 nM 850 nM N/A
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*Genes with common alternative names are in parentheses, and those related to the PI3K, MEK, or PDGFR pathways are in bold
 1486
AURKB), and extracellular receptors (PDGFRα/β, EPHA1/3, 
EPHB1/3, INSR, VEGFR1) (Table  1, Supplementary Table 
S2). With PI3K inhibition, the MAPK cascade (TAO1, 
MEK1/MEK2, ERK2, RSK1/2, DUSP21), cell cycle regula-
tion (AURKA), and extracellular receptors (EFNA3/B3, 
EPHB1, TGFβR1) (Table 1, Supplementary Table S2) were 
synthetically lethal. Both selumetinib and buparlisib 
treatment yielded cross-validation of the MEK+PI3K com-
bination as being synthetically lethal in 2 of our 4 TNBC 
cell lines, and identified MEK+PDGFR as another possible 
combination.
Small Molecule PI3K, MEK, or PDGFR Inhibitors 
Reduce Cell Growth in Human-Derived TNBC 
Cell Lines
The effects of PI3K, MEK, or PDGFR inhibitors were evalu-
ated in 4 TNBC cell lines (SUM149, 231Br, MDA-MB-436, 
and MDA-MB-468) representing both heterogene-
ous molecular subtypes and mutational backgrounds 
(Fig.  1A). Exposure to buparlisib (PI3Ki), selumetinib 
(MEKi), and pazopanib (PDGFRi) in vitro demonstrated 
differential patterns of drug responses based on cell via-
bility. For buparlisib, all 4 models exhibited similar IC50 
responses (1.3–1.9 µM) but variable GI50 (1.4–11.7 µM) and 
Imax (92%–49%) values (Fig. 1B, Supplementary Table S3). 
Selumetinib had a higher potency in the SUM149 and 
231Br models (IC50: 0.8–19.3 µM) relative to the 468 and 436 
models (IC50: 97.0–220.7 µM) (Fig. 1C, Supplementary Table 
S3). Pazopanib yielded similar IC50 (4.1–10  µM) but was 
relatively ineffective (GI50: never reached; Imax: 13%–30%; 
Fig. 1D, Supplementary Table S3).
Synergistic Combination of PI3K+MEK and 
PDGFR+MEK
In comparing the combination index (CI) to fraction affected 
(FA), dual buparlisib + selumetinib exposure was syner-
gistic. Synergism occurs in all 4 cell lines (Fig.  1E). This 
synergy was generally greater (lower CI) in the SUM149 
and 231Br lines compared with the 468 and 436 lines and 
occurred at lower absolute drug concentrations, due to the 
relatively lower IC50 concentrations in the SUM149 and 
231Br lines (Fig.  1E). Similar results were obtained with 
the selumetinib + pazopanib combination. In the SUM149 
and 231Br models, dual selumetinib+pazopanib treatment 
was synergistic at or below the IC50, in contrast to the 468 
and 436 models (Fig.  1F). Thus, both the PI3K+MEK and 
MEK+PDGFR combinations are synergistic at potentially 
physiologically relevant concentrations in SUM149 and 
231Br, but not 468 and 436 cell lines.
PI3K+MEK Inhibition Improves Survival and 
Reduces Tumor Burden in Some Intracranial 
TNBC Models
We tested the survival and efficacy of buparlisib ± selu-
metinib in mice with intracranial TNBC (Fig. 2A). In the 
SUM149 model, survival significantly improved from 
controls (45 days) with buparlisib (52 days; P = 0.003) 
and selumetinib (72 days, P = 0.004; Fig. 2B, C). A simi-
lar effect on tumor burden was observed in response 
to single agents, with buparlisib slightly reducing 
and selumetinib greatly reducing tumor burden rela-
tive to controls (Supplementary Fig. S1A, B). Daily 
buparlisib+selumetinib modestly improved survival (50 
days, P = 0.023), but with continued daily weight loss. 
Thus, we tested a 5 days on/2 days off schedule (5-2), 
which significantly improved survival while avoiding 
toxicity (87 days; P of 5-2 vs control: <0.0001; buparlisib: 
0.0077; selumetinib: 0.17; Fig. 2B, C). Further, a third (4/12) 
of the mice on 5-2 combination treatment were alive 
at the end of the study compared with 0/11 mice in the 
controls, 1/13 with buparlisib, and 3/13 with selumetinib. 
Reduction in tumor burden was most profound in the 
daily combination treatment group (Supplementary Figs 
S1B, S2A–F).
The MDA-MB-231Br model demonstrated a similar 
sensitivity to the buparlisib+selumetinib combination. 
Buparlisib alone did not improve survival (29 days) relative 
to the control group (30 days; P  = 0.39), but selumetinib 
did (37  days; P  =  0.014; Fig.  2B, D). Again, toxicity from 
daily buparlisib+selumetinib precluded improved survival 
(31 days; P = 0.31), but administration on a 5-2 schedule 
increased survival (55 days; P of 5-2 vs controls: <0.0001; 
buparlisib: 0.0004; selumetinib: 0.058; overall P < 0.0001). 
Treatment with selumetinib, alone or combined with 
buparlisib, reduced tumor burden relative to controls 
(Supplementary Figs S1C, S2G–L).
In contrast, the MDA-MB-468 and MDA-MB-436 intrac-
ranial TNBC murine models did not show significant 
improvements in survival or reduction in tumor bur-
den with buparlisib and/or selumetinib (overall P 468: 
0.12; 436: 0.35; Fig. 2B, E, F; Supplementary Figs S1D–E, 
S2M–X).
Buparlisib and Selumetinib Differentially 
Inhibit Downstream Targets in Intracranial 
TNBC Tumors
Target inhibition was compared in 231Br (responsive) 
and 468 (resistant) intracranial tumors after 14  days of 
treatment. The ratio of phosphorylated to total protein 
of ERK/MEK and Akt were used as markers of MEK and 
PI3K pathway inhibition, respectively. Intracranial 231Br 
tumors treated with selumetinib  ±  buparlisib daily had 
significantly reduced pERK/ERK ratios compared with 
controls (overall P  =  0.025) (Fig.  3A, B). Similarly, daily 
exposure to buparlisib and/or selumetinib significantly 
reduced pAkt/Akt ratios in 231Br intracranial tumors 
(overall P = 0.0011) (Fig. 3A, C). Finally, selumetinib alone 
or combined with buparlisib on a daily or 5-2 schedule 
maintained MEK inhibition in the 231Br model (overall 
P  = 0.013) (Fig.  3A, D). In contrast, phosphorylated and 
total levels of ERK or Akt in the 468 model were similar 
across treatment groups (Supplementary Fig. S3A–C), 
while pMEK/MEK ratios increased with selumetinib treat-
ment (overall P = 0.017; Supplementary Fig. S3D). Thus, 
the responsive 231Br demonstrates target inhibition and 
improved survival, while the resistant 468 model main-
tains MEK and PI3K signaling despite ongoing treatment.
Widespread Reprogramming of the Kinome 
Follows PI3K and/or MEK Treatment in 
Intracranial SUM149 Tumors
An affinity chromatography technique using multiplexed 
inhibitor beads (MIB) coupled with mass spectrometry 
(MS) was used to assess the functional kinome in response 
to drug treatment. In intracranial SUM149 tumors, wide-
spread alterations in kinase binding to the beads occurred, 
but with varying kinome families activated with each 
treatment (Fig. 4). Forty-eight of 251 kinases captured 
were significantly different across treatments (Q < 0.1, 
Fig. 2 In vivo efficacy of PI3K ± MEK inhibition in established intracranial TNBC. (A) Experimental schedule. (B) The median survival (MS) and 
number of mice alive at the end of the study for mice with intracranial SUM149, MDA-MB-231Br, MDA-MB-468, or MDA-MB-436 tumors. Median 
survival (MS) for treatment groups statistically different from control (*) or buparlisib (^). Kaplan–Meier curves by treatment group for the (C) 
SUM149, (D) MDA-MB-231Br, (E) MDA-MB-468, and (F) MDA-MB-436 models. Vertical dotted lines indicate the study’s end.
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Supplementary Table S4). Of these, 9/48 kinases over-
lapped in at least one pairwise comparison between con-
trol and treatment. Relative to control-treated tumors, 
buparlisib significantly altered the levels of 5 kinases: 
insulin receptor (INSR), insulin-like growth factor 1 recep-
tor (IGF1R), fibroblast growth factor receptor 2 (FGFR2), 
mitogen-activated protein kinase kinase kinase kinase 
4 (MAP4K4), and thousand-and-one amino acid kinase 
1 (TAOK1) (Supplementary Fig. S4A–E, Supplementary 
Table S5). Selumetinib treatment caused a reduction 
only in MAP4K4 (Supplementary Table S6). In contrast, 
buparlisib+selumetinib significantly altered binding of the 
most responsive kinases across all treatment groups (n 
= 7/9) relative to controls: INSR, FGFR2, MAP4K4, riboso-
mal protein S6 kinase B1 (RPS6KB1), pyridoxine, vitamin 
B6 kinase (PDXK), the “rearranged during transfection” 
gene (RET), and tyrosine nonreceptor kinase 2 (TNK2) 
(Supplementary Fig. S4A, C–D, F–I, Supplementary Table 
S7).
PDGFR+MEK Inhibition as a Tractable 
Therapeutic Strategy in Intracranial TNBC
As a result of the siRNA kinome screen and in vitro syn-
ergy studies, we also evaluated PDGFR+MEK in SUM149 
and 231Br. In the SUM149 model, pazopanib (PDGFRi) 
did not improve median survival (37.5 vs 34 days in con-
trols; overall P < 0.0001; pairwise P = 0.66), whereas sel-
umetinib demonstrated efficacy (63  days; P  <  0.0001) 
Fig. 3 Western blot analysis of MEK ± PI3K inhibitor treatment in MDA-MB-231Br. (A) Immunoblots of phosphorylated (p-) and total ERK, Akt, 
and MEK in control, selumetinib, buparlisib, combination (“combo”) daily, and combo 5-2 treated tumors, n = 4 per group. Quantitation of (B) 
pERK to total ERK, (C) pAkt to Akt, and (D) pMEK to MEK levels by densitometry of immunoblot bands from (A). Overall P shown; *pairwise vs 
control P ≤ 0.05.
Fig. 4 Kinome alteration following 2 weeks of treatment with buparlisib, selumetinib, or combination in intracranial SUM149 TNBC tumors. (A) 
Fold change of kinases comparing buparlisib (green), selumetinib (blue), or combination (red) relative to controls. Only kinases with a Log2 fold 
change of >0.5 or <−0.5 in any treatment group relative to controls are shown. B‒D. Kinome tree diagrams of altered kinases following (B) bupar-
lisib, (C) selumetinib, and (D) combination, colored by fold change relative to controls: ≥2x (red), 1.5x–2x (pink), ≤0.5x (blue), unchanged (black), 
detected only in treatment (gray).
(Fig.  5A‒B). Combined daily pazopanib+selumetinib sig-
nificantly improved survival (92.5  days; P  <  0.0001) and 
drastically reduced tumor burden (Fig.  5C). Western blot 
analysis showed reduction of pERK/ERK with 2 weeks of 
selumetinib or combination treatment (P = 0.015), but no 
change in pAkt/Akt (Supplementary Fig. 5C).
Results were more modest in the 231Br model. Single 
agent pazopanib did not alter median survival (24 days vs 
Fig. 5 Efficacy of PDGFR+MEK inhibition. (A) Median survival (MS) and number of mice alive at the study’s end for intracranial SUM149 and 
MDA-MB-231Br tumors, statistically different from control (*), pazopanib (^), selumetinib (~). SUM149 (B) MS and (C) in vivo intracranial tumor 
burden by treatment group. MDA-MB-231Br (D) MS and (E) tumor burden by treatment group. Vertical dotted lines indicate study’s end per 
IACUC-approved protocols. N/D = not determined.
1491
28  days in controls; overall P  =  0.0072; pairwise P  =  0.94) 
(Fig. 5A, D). Pazopanib+selumetinib modestly improved sur-
vival (38 days; P = 0.016) and reduced tumor burden (Fig. 5E).
Discussion
Herein, we demonstrate hypothesis-driven discovery of 2 
rational combinatorial approaches for the treatment of intrac-
ranial triple-negative breast cancer (TNBC). Examining 4 
intracranial TNBC models, the combination of MEK+PI3K and 
MEK+PDGFR inhibitors increased survival and decreased 
tumor burden in 2 models and induced kinome-wide altera-
tions in 1 model. We demonstrate effective intracranial tumor 
penetration of and a durable response to the combination of 
these 3 clinically approved therapies in 2 models.
This work supports growing appreciation that combina-
tion therapy must be utilized to effectively target cancer. 
Due to dynamic resistance mechanisms in breast cancer, 
monotherapy is not an effective strategy for treating TNBC. 
Concurrent inhibition of MEK+PI3K or MEK+PDGFRα/β has 
been suggested as a rational partnering strategy in primary 
breast cancer.17,18 This study is the first, to our knowledge, 
to demonstrate efficacy of rational MEK inhibitor combina-
tion strategies in multiple orthotopic models of TNBC brain 
metastases, established or otherwise.
Our data illustrate potentially targetable resistance mech-
anisms to kinase inhibitors, including the INSR/IGF1R and 
FGFR2 pathways. Prior literature has demonstrated heter-
odimerization of INSR+IGF1R and IGF1R+PDGFR receptors, 
activating the PI3K and MAPK pathways.37 Interestingly, 
buparlisib+selumetinib treatment in the SUM149 model 
also increased 2 kinases, RET and TNK2, associated with 
both neuronal/synaptic functions and cancer progres-
sion.38,39 Alteration of neuronal kinases as resistance 
mechanisms adds to recent literature suggesting a “breast-
to-brain” transition wherein cancer cells express neuronal-
like features that confer survival advantages.40,41
The results of the present study should be interpreted in 
the context of the following limitations. Substantial toxicity 
of the MEK+PI3K inhibitor treatment, as seen in our data, 
is an important consideration in the clinical applicability 
of this approach. Continued weight loss (data not shown) 
and ultimate demise of the animals (Fig.  2C‒D) despite 
stable tumor burden (Supplementary Fig. S1B–C) in both 
the SUM149 and MDA-MB-231Br models occurred on daily 
combination therapy. As has been reported in the clinical 
setting, the incorporation of a weekly drug holiday signifi-
cantly improved survival by abating toxicity.42,43 MEK+PI3K 
inhibition has dose limiting toxicities of stomatitis, diar-
rhea, and creatinine kinase elevation in <10% of patients, 
with many patients (65%) exhibiting grade 3–4 adverse 
events of those above plus aspartate aminotransferase/ala-
nine aminotransferase elevations and rashes.43 Pazopanib 
induces similar manageable gastrointestinal events (ie, 
diarrhea, nausea, vomiting, and anorexia) and fatigue.44,45 
Further investigation into strategies that manage toxic-
ity while maintaining efficacy with these treatments are 
needed. Secondly, our direct intracranial implantation 
method addresses whether these agents are effective in 
treating established BM, mimicking the current clinical 
approach, and not leptomeningeal disease or as a preven-
tative measure blocking TNBC brain metastases. Finally, 
the use of immunocompromised mice precludes study on 
the effects of MEK inhibition on the immune system and its 
involvement in the treatment response, a direction worthy 
of further study.
The present study demonstrates that models of estab-
lished intracranial TNBC exhibit differential sensitivity to 
targeted therapies, highlighting the need to test multiple 
models when evaluating potential treatment strategies. The 
differential responses in our models are likely due in part 
to the molecular heterogeneity of TNBC, which comprises 
as many as 6 subtypes, each with unique responsiveness 
to treatment and outcome.46,47 We continue to explore the 
underlying mechanism of differential sensitivity to MEK 
inhibition in intracranial TNBC. Identification and valida-
tion of biomarkers predictive of sensitivity or resistance to 
MEK inhibition will foster the most effective translation of 
our preclinical findings to the design of biomarker-driven, 
early-phase clinical trials to more effectively treat patients 
with TNBC BM.
Supplementary Material
Supplementary material is available at Neuro-Oncology 
online.
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